### ASSESSMENT

A concise history, examination and biopsychosocial assessment, identifying pain type (neuropathic/nociceptive/mixed), severity, functional impact and context should be conducted in all patients with chronic pain. This will inform the selection of treatment options most likely to be effective.

Referral should be considered when non-specialist management is failing, chronic pain is poorly controlled, there is significant distress, and/or where specific specialist intervention or assessment is considered.

A compassionate, patient-centred approach to assessment and management of chronic pain is likely to optimise the therapeutic environment and improve the chances of successful outcome.

### SUPPORTED SELF MANAGEMENT

C Self-management resources should be considered to complement other therapies in the treatment of patients with chronic pain.

Healthcare professionals should signpost patients to self-help resources, identified and recommended by local pain services, as a useful aide at any point throughout the patient journey. Self management may be used from an early stage of a pain condition through to use as part of a long-term management strategy.

### PHARMACOLOGICAL THERAPIES

Patients using analgesics to manage chronic pain should be reviewed.

<table>
<thead>
<tr>
<th>Non-opioid analgesics (simple and topical)</th>
<th>Opioids</th>
<th>Antidepressants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAIDs</strong> should be considered in the treatment of patients with chronic non-specific low back pain.</td>
<td><strong>Opioids should be considered for short- to medium-term treatment of carefully selected patients with chronic non-malignant pain, for whom other therapies have been insufficient, and the benefits may outweigh the risks of serious harms such as addiction, overdose and death.</strong></td>
<td><strong>Patients with chronic pain conditions using antidepressants should be reviewed regularly and assessed for ongoing need and to ensure that the benefits outweigh the risks.</strong></td>
</tr>
<tr>
<td>Cardiovascular and gastrointestinal risk needs to be taken into account when prescribing any non-steroidal anti-inflammatory drug.</td>
<td>At initiation of treatment, ensure there is agreement between prescriber and patient about expected outcomes (see Annex 4 of the full guideline). If these are not attained, then there should be a plan agreed in advance to reduce and stop opioids.</td>
<td><strong>Tricyclic antidepressants should not be used for the management of pain in patients with chronic low back pain.</strong></td>
</tr>
<tr>
<td>Paracetamol (1,000–4,000 mg/day) should be considered alone or in combination with NSAIDs in the management of pain in patients with hip or knee osteoarthritis in addition to non-pharmacological treatments.</td>
<td>All patients on opioids should be assessed early after initiation, with planned reviews thereafter. These should be reviewed annually, at a minimum, but more frequently if required. The aim is to achieve the minimum effective dose and avoid harm. Treatment goals may include improvements in pain relief, function and quality of life. Consideration should be given to a gradual early reduction to the lowest effective dose or complete cessation.</td>
<td><strong>Amitriptyline (25–125 mg/day) should be considered for the treatment of patients with fibromyalgia and neuropathic pain (excluding HIV-related neuropathic pain).</strong></td>
</tr>
<tr>
<td><strong>Topical NSAIDs</strong> should be considered in the treatment of patients with chronic pain from musculoskeletal conditions, particularly in patients who cannot tolerate oral NSAIDs.</td>
<td><strong>Currently available screening tools should not be relied upon to obtain an accurate prediction of patients at risk of developing problem opioid use, but may have some utility as part of careful assessment either before or during treatment.</strong></td>
<td><strong>It may be appropriate to try alternative tricyclic antidepressants to reduce the side effect profile.</strong></td>
</tr>
<tr>
<td><strong>Topical capsaicin patches</strong> (8%) should be considered in the treatment of patients with peripheral neuropathic pain when first-line pharmacological therapies have been ineffective or not tolerated.</td>
<td><strong>Signs of abuse, addiction and/or other harms should be sought at reassessment of patients using strong opioids.</strong></td>
<td><strong>Duloxetine (60 mg/day) should be considered for the treatment of patients with diabetic neuropathic pain if other first- or second-line pharmacological therapies have failed.</strong></td>
</tr>
<tr>
<td><strong>Topical lidocaine</strong> should be considered for the treatment of patients with postherpetic neuralgia if first-line pharmacological therapies have been ineffective.</td>
<td><strong>All patients receiving opioid doses of &gt;50 mg/day morphine equivalent should be reviewed regularly (at least annually) to detect emerging harms and consider ongoing effectiveness. Pain specialist advice or review should be sought at doses &gt;90 mg/day morphine equivalent.</strong></td>
<td><strong>Duloxetine (60 mg/day) should be considered for the treatment of patients with fibromyalgia or osteoarthritis.</strong></td>
</tr>
<tr>
<td><strong>Topical rubifacients</strong> should be considered for the treatment of pain in patients with musculoskeletal conditions if other pharmacological therapies have been ineffective.</td>
<td><strong>Antiepilepsy drugs</strong></td>
<td><strong>Fluoxetine (20–80 mg/day) should be considered for the treatment of patients with fibromyalgia.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Optimised antidepressant therapy should be considered for the treatment of patients with chronic pain with moderate depression.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Depression is a common comorbidity with chronic pain. Patients should be monitored and treated for depression when necessary.</strong></td>
</tr>
</tbody>
</table>

### Combination therapies

A **Combination therapies should be considered for patients with neuropathic pain (a pathway for patients with neuropathic pain can be found in Annex 3 of the full guideline).**

A In patients with neuropathic pain who do not respond to gabapentinoid (gabapentin/pregabalin) alone, and who are unable to tolerate other combinations, consideration should be given to the addition of an opioid such as morphine or oxycodone. The risks and benefits of opioid use needs to be considered.

### PSYCHOLOGICALLY BASED INTERVENTIONS

A Healthcare professionals referring patients for psychological assessment should attempt to assess and address any concerns the patient may have about such a referral. It may be helpful to explicitly state that the aims of psychological interventions are to increase coping skills and improve quality of life when faced with the challenges of living with pain.

### Pain management programmes

C **Referral to a pain management programme should be considered for patients with chronic pain.**

### Unidisciplinary education

C Brief education should be given to patients with chronic pain to help patients continue to work.
Evidence

This Quick Reference Guide provides a summary of the main recommendations in SIGN 136 Management of chronic pain. Recommendations are graded A B C D to indicate the strength of the supporting evidence.

Good practice points ✓ are provided where the guideline development group wishes to highlight specific aspects of accepted clinical practice.

Details of the evidence supporting these recommendations can be found in the full guideline, available on the SIGN website: www.sign.ac.uk.

This Quick Reference Guide is also available as part of the SIGN Guidelines app.

Sources of Further Information

National Chronic Pain Website for Scotland
www.chronicpainscotland.org

British Complementary Medicine Association
P.O. Box 5122, Bournemouth, BH8 0WG
Tel: 0845 345 5977
www.bcma.co.uk

British Pain Society
Third Floor, Churchill House, 35 Red Lion Square, London WC1R 4SG
Tel: 020 7269 7840
www.britishpainsociety.org • Email: info@britishpainsociety.org

Chronic Pain Policy Coalition
Policy Connect, CAN Mezzanine, 32–36 Loman Street, London, SE1 0EH
Tel: 020 7202 8280
www.policyconnect.org.uk/cppc • E-mail: rachel.downing@policyconnect.org.uk

Health and Social Care Alliance Scotland
Venlaw Building, 349 Bath Street, Glasgow, G2 4AA
Tel: 0141 404 0231 • Fax: 0141 246 0348
www.alliance-scotland.org.uk • E-mail: info@alliance-scotland.org.uk

Healthtalkonline Database
www.healthtalkonline.org

NHS Inform
www.nhsinform.co.uk

Pain Association Scotland
Suite D, Moncrieffe Business Centre, Friarton Road, Perth, PH2 8DG
Tel: 0800 783 6059
www.painsociation.com • Email: info@painsociation.com

Pain Concern
Unit 1-3, 62-66 Newcairn Road, Fort Kinnaird, Edinburgh, EH15 3HS
Tel: 0131 669 5951 • Helpline: 0300 123 0789
www.painconcern.org.uk • Email: info@painconcern.org.uk

Pain Support
www.painsupport.co.uk

Pain UK
www.painuk.org